Residency · Residency · Gastroenterology

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

Primary Biliary Cholangitis (PBC)

Overview

Primary biliary cholangitis is a chronic autoimmune cholestatic liver disease that selectively targets the small intrahepatic bile ducts, leading to progressive ductopenia, cholestasis, and biliary fibrosis. The disease was previously designated primary biliary cirrhosis, but was renamed in 2015 to more accurately reflect the clinical reality that the majority of patients do not have cirrhosis at the time of diagnosis. PBC demonstrates a striking female predominance of approximately 9:1, with a peak age of onset between 40 and 60 years, and affects all ethnicities.

Pathogenesis

The pathogenesis of PBC centers on a loss of immune tolerance to mitochondrial antigens, specifically the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). Biliary epithelial cells undergo apoptosis and expose immunogenic PDC-E2 epitopes, which are uniquely preserved on the apoptotic cell surface in biliary epithelium. This triggers activation of both CD4-positive and CD8-positive T cells, as well as the generation of anti-mitochondrial antibodies (AMA). The immune-mediated destruction of small bile ducts manifests histologically as the florid duct lesion, characterized by granulomatous inflammation targeting bile ducts measuring less than 100 micrometers in diameter.

As bile duct destruction progresses, progressive ductopenia ensues, leading to impaired bile flow and intrahepatic cholestasis. The retained toxic hydrophobic bile acids cause further hepatocyte injury, activating hepatic stellate cells and driving biliary fibrosis that ultimately progresses to biliary cirrhosis in untreated patients.

Clinical Presentation

Approximately 50 to 60% of patients are asymptomatic at the time of diagnosis, identified through incidental detection of cholestatic liver enzymes on routine laboratory testing. Fatigue is the most common symptom, affecting 50 to 80% of patients. It is characteristically disproportionate to the severity of liver disease, does not correlate with histologic stage, and is often profoundly debilitating. Unfortunately, treatment options for PBC-associated fatigue remain limited.

Pruritus affects 20 to 70% of patients and may precede the onset of jaundice by years. The mechanism involves cholestasis-mediated activation of the autotaxin/lysophosphatidic acid pathway. Sicca syndrome with dry eyes and dry mouth occurs in 40 to 50% of patients, reflecting the frequent association with Sjogren syndrome. Jaundice is a late manifestation indicating advanced disease with significant ductopenia and impaired biliary excretion.

Hyperlipidemia with elevated cholesterol may produce xanthelasma and xanthoma, though paradoxically this lipid elevation is not associated with increased cardiovascular risk. Metabolic bone disease, particularly osteoporosis, occurs in 20 to 35% of patients as a consequence of cholestasis-impaired vitamin D absorption. PBC is associated with numerous autoimmune conditions, including Sjogren syndrome (35%), thyroid disease (15 to 25%), scleroderma (particularly the CREST variant), celiac disease, and rheumatoid arthritis.

Diagnosis

The biochemical hallmark is elevation of alkaline phosphatase, typically 2 to 10 times the upper limit of normal, with normal or mildly elevated bilirubin in early disease. Elevated gamma-glutamyl transferase confirms the biliary origin of the alkaline phosphatase elevation. Anti-mitochondrial antibody is the serologic cornerstone of diagnosis, positive in 90 to 95% of PBC patients at a titer of 1:40 or greater. AMA targets the PDC-E2 subunit and has a specificity exceeding 95% for PBC.

AMA-negative PBC occurs in 5 to 10% of cases. In these patients, ANA testing may reveal highly PBC-specific patterns: anti-sp100 antibodies producing a nuclear dots pattern, or anti-gp210 antibodies producing a nuclear rim pattern. Elevated polyclonal IgM further supports the diagnosis.

Liver biopsy is not required for diagnosis when alkaline phosphatase is elevated and AMA is positive. Biopsy is indicated for staging, when overlap syndromes are suspected, or in AMA-negative cases. The histologic staging system progresses through four stages: stage 1 features portal inflammation with the florid duct lesion (granulomatous cholangitis); stage 2 demonstrates periportal hepatitis with ductular proliferation; stage 3 shows fibrous septa and bridging fibrosis; and stage 4 represents established cirrhosis.

Treatment

First-Line: Ursodeoxycholic Acid (UDCA)

Ursodeoxycholic acid at 13 to 15 mg/kg/day divided into two or three doses is the established first-line therapy for PBC. UDCA functions by displacing toxic hydrophobic bile acids from the bile acid pool, exerting choleretic effects that enhance bile flow, and providing anti-inflammatory and anti-apoptotic cytoprotective effects on biliary epithelium.

Treatment response is assessed at 12 months using validated biochemical criteria. The Paris I criteria require alkaline phosphatase below 3 times the upper limit of normal, AST below 2 times the upper limit of normal, and bilirubin at or below 1 mg/dL. The Paris II criteria set more stringent thresholds of alkaline phosphatase and AST below 1.5 times the upper limit of normal with normal bilirubin. The Toronto criteria require alkaline phosphatase below 1.67 times the upper limit of normal, and the Barcelona criteria require a greater than 40% decline in alkaline phosphatase or normalization.

Approximately 40% of patients demonstrate an inadequate response to UDCA, necessitating the addition of second-line therapy. Transplant-free survival in UDCA responders approaches that of the age- and sex-matched general population, while non-responders face significantly reduced survival.

Second-Line: Obeticholic Acid (OCA)

Obeticholic acid is a farnesoid X receptor agonist administered at an initial dose of 5 mg per day, with titration to 10 mg per day at 6 months. The POISE trial demonstrated significant reduction in alkaline phosphatase and bilirubin in patients with inadequate UDCA response. Side effects include dose-dependent pruritus that is severe in 10 to 25% of patients, and a paradoxical increase in LDL cholesterol. A critical safety concern is the contraindication in decompensated cirrhosis, for which the FDA has issued a boxed warning after reports of hepatic decompensation and death. In patients with Child-Pugh B or C cirrhosis, the dose must be reduced to 5 mg weekly rather than daily, though the drug is generally avoided in this population.

Second-Line: Elafibranor

Elafibranor is a PPARalpha/delta agonist administered at 80 mg daily. The ELATIVE trial demonstrated alkaline phosphatase normalization or near-normalization with bilirubin improvement in UDCA non-responders. The drug was FDA-approved in 2024 for PBC with inadequate UDCA response and offers a more favorable side effect profile than obeticholic acid, with less pruritus.

Second-Line: Seladelpar

Seladelpar is a selective PPARdelta agonist administered at 10 mg daily. The ENHANCE trial demonstrated significant improvement in alkaline phosphatase and bilirubin in UDCA non-responders. It was FDA-approved in 2024 for PBC and is well tolerated, with less pruritus than obeticholic acid.

Fibrate Add-On Therapy

Bezafibrate at 400 mg daily was evaluated in the BEZURSO trial conducted in France, which demonstrated significant alkaline phosphatase improvement and symptom benefit when added to UDCA. While not FDA-approved for PBC, bezafibrate is used off-label, particularly in Europe and Canada. Fenofibrate at 200 mg daily has also been used off-label, though with less robust evidence than bezafibrate. Liver function tests and creatinine should be monitored during fibrate therapy.

Symptom Management

Pruritus

The management of cholestatic pruritus follows a stepwise approach. Cholestyramine at 4 grams one to four times daily is the first-line agent. It acts as a bile acid sequestrant, and must be administered 2 to 4 hours apart from UDCA to avoid binding and inactivating the therapeutic bile acid. Poor palatability and gastrointestinal intolerance limit its use.

Rifampin at 150 to 300 mg twice daily is the most effective pharmacologic agent for cholestatic pruritus and is considered second-line. Its mechanism involves induction of bile acid detoxification enzymes and upregulation of the pregnane X receptor. Hepatotoxicity necessitates monitoring of liver function tests every 2 to 4 weeks initially and every 3 months thereafter.

Naltrexone at 25 to 50 mg daily addresses the opioidergic component of cholestatic pruritus. It may precipitate an opioid withdrawal-like syndrome at initiation, and doses should be titrated gradually. Sertraline at 75 to 100 mg daily provides modest benefit. Emerging agents include ileal bile acid transporter inhibitors such as linerixibat and maralixibat, which are under investigation for cholestatic pruritus. For intractable pruritus refractory to all pharmacologic interventions, plasmapheresis or albumin dialysis using the Molecular Adsorbent Recirculating System (MARS) may serve as a bridge to liver transplantation.

Fatigue

No consistently effective therapy exists for PBC-associated fatigue. Contributing factors such as anemia, thyroid dysfunction, depression, and sleep apnea should be identified and treated. Modafinil at 100 to 200 mg daily has limited evidence of benefit. A structured exercise program may improve fatigue perception.

<image>A PBC treatment algorithm and response assessment diagram. Start with "Diagnosed PBC (elevated ALP + AMA positive)." First step: "UDCA 13-15 mg/kg/day." At 12 months: "Assess treatment response using validated criteria (Paris I/II, Toronto)." Two branches: (1) "Adequate UDCA response (ALP <1.67x ULN or Paris criteria met)": "Continue UDCA; monitor LFTs q6 months; DEXA scan; annual thyroid function; transplant-free survival approaches normal." (2) "Inadequate UDCA response": "Add second-line agent: Elafibranor 80 mg daily (PPARalpha/delta, FDA 2024) OR Seladelpar 10 mg daily (PPARdelta, FDA 2024) OR Obeticholic acid 5-10 mg daily (FXR agonist, AVOID in decompensated cirrhosis) OR Bezafibrate 400 mg daily (off-label, best evidence from BEZURSO)." Reassess at 6-12 months. Include a "Pruritus management" sidebar with stepwise escalation: Step 1 cholestyramine, Step 2 rifampin, Step 3 naltrexone/sertraline, Step 4 IBAT inhibitors/plasmapheresis. Include prognostic model box: GLOBE score and UK-PBC score predict transplant-free survival based on UDCA response variables. Use green for good response, yellow for inadequate response, red for advanced/decompensated disease requiring transplant evaluation.</image>

Primary Sclerosing Cholangitis (PSC)

Overview

Primary sclerosing cholangitis is a chronic cholestatic liver disease characterized by progressive inflammation and fibrosis of the intrahepatic and/or extrahepatic bile ducts, leading to multifocal stricturing, cholestasis, and ultimately biliary cirrhosis. In contrast to PBC, PSC demonstrates a male predominance of approximately 2:1 with a peak age of onset between 30 and 40 years.

The association between PSC and inflammatory bowel disease is one of the strongest disease-disease associations in medicine. Sixty to 80% of PSC patients have concurrent inflammatory bowel disease, predominantly ulcerative colitis. However, only 5 to 8% of ulcerative colitis patients develop PSC. The PSC-IBD colitis phenotype is distinctive, often manifesting as pancolitis with rectal sparing and backwash ileitis. Although the colitis itself may run a mild clinical course, PSC-IBD confers a 4-fold increased risk of colorectal cancer compared with ulcerative colitis alone.

Pathogenesis

The pathogenesis of PSC remains incompletely understood and is likely immune-mediated in genetically susceptible individuals. HLA associations include HLA-B8, HLA-DR3, and HLA-DR2, and more than 50 non-HLA risk loci have been identified, including variants in IL2, IL2RA, and BACH2.

The gut-liver axis is central to current pathogenic models. Aberrant lymphocyte homing from the gut to the liver, mediated by the alpha4-beta7 integrin and MAdCAM-1 pathway, may direct gut-primed inflammatory cells to target the biliary epithelium. Gut-derived bacterial products and bile acid dysregulation further contribute to biliary inflammation. The hallmark histologic lesion is periductal concentric "onion-skinning" fibrosis surrounding medium and large bile ducts, which progresses to bile duct stricturing and obliteration, culminating in secondary biliary cirrhosis.

Clinical Presentation

Approximately 40 to 50% of patients are asymptomatic at diagnosis, identified through incidental detection of cholestatic liver enzymes. When symptomatic, patients present with fatigue, pruritus, right upper quadrant pain, and intermittent or progressive jaundice. Recurrent episodes of bacterial cholangitis occur, particularly following endoscopic interventions. Dominant strictures, defined as focal high-grade strictures of the common bile duct or hepatic duct, produce symptomatic biliary obstruction and must be evaluated to exclude cholangiocarcinoma.

Diagnosis

Cholangiography is the gold standard for diagnosing PSC. Magnetic resonance cholangiopancreatography is the preferred initial study, offering non-invasive visualization of the biliary tree with a sensitivity of 86% and specificity of 94%. The characteristic findings are multifocal short-segment strictures alternating with dilated segments, producing a "beading" or "pruned tree" appearance. Endoscopic retrograde cholangiopancreatography is reserved for therapeutic interventions such as dominant stricture dilation and tissue sampling for cytology, as it carries a higher complication rate including pancreatitis and cholangitis.

Alkaline phosphatase is typically elevated at 2 to 5 times the upper limit of normal and characteristically fluctuates over time. Perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) of the atypical pattern are positive in 60 to 80% of PSC patients. While not diagnostic, pANCA positivity provides supportive evidence. IgG4 levels should be checked in all patients to exclude IgG4-associated sclerosing cholangitis, a distinct disease entity with different treatment implications. IgG4 is elevated in 10 to 15% of PSC patients, but this elevation does not always indicate IgG4-sclerosing cholangitis.

Liver biopsy is not required when typical cholangiographic findings are present. The classic periductal concentric fibrosis is seen in only 30 to 40% of biopsies. Biopsy is most useful in the diagnosis of small-duct PSC, which presents with normal cholangiography.

Small-Duct PSC

Small-duct PSC accounts for 5 to 10% of PSC cases and is defined by cholestatic biochemistry with histologic features consistent with PSC but a normal cholangiogram. This variant carries a better prognosis than large-duct PSC and has a lower risk of cholangiocarcinoma. Approximately 10 to 20% of small-duct PSC patients progress to large-duct PSC over 10 years.

Treatment -- No Proven Disease-Modifying Therapy

Unlike PBC, no pharmacologic therapy has been proven to modify disease progression in PSC. UDCA at standard doses of 13 to 15 mg/kg/day may improve biochemical markers but has not demonstrated impact on transplant-free survival, histologic progression, or mortality. High-dose UDCA at 28 to 30 mg/kg/day is harmful, as demonstrated in a randomized controlled trial by Lindor (2009) that showed increased adverse events, and must not be used.

Active clinical trials are investigating norUDCA, farnesoid X receptor agonists, ileal bile acid transporter inhibitors, anti-fibrotic agents, and microbiome modulation strategies. Endoscopic management of dominant strictures through ERCP with balloon dilation with or without short-term stenting improves cholestasis symptoms and biochemical parameters. Brush cytology should be obtained during these procedures to evaluate for cholangiocarcinoma. Symptom management follows the same approaches used for PBC, including pruritus therapy and fat-soluble vitamin supplementation. Metabolic bone disease management is similarly important.

Liver transplantation is the definitive treatment for PSC and is indicated for decompensated cirrhosis, recurrent cholangitis, intractable pruritus, and cholangiocarcinoma in select protocols. Outcomes are excellent, with 5-year survival exceeding 80%. Recurrence of PSC after transplantation occurs in 20 to 25% of patients at 10 years.

Malignancy Surveillance -- Critical

Cholangiocarcinoma is the most feared complication of PSC, with a lifetime risk of 7 to 15% and an annual incidence of 0.5 to 1.5%. Cholangiocarcinoma may occur early in the disease course, even at the time of PSC diagnosis, and is notoriously difficult to detect at an early stage. Annual MRCP and CA 19-9 measurement are recommended for surveillance, though neither modality has sufficient sensitivity to detect early cholangiocarcinoma reliably.

When a dominant stricture is identified, ERCP with cytology brushings should be performed, and fluorescence in situ hybridization for chromosomal polysomy should be obtained to improve diagnostic sensitivity to 50 to 70%. Cholangiocarcinoma in PSC is generally a contraindication to liver transplantation, except under specialized protocols such as the Mayo Clinic protocol, which employs neoadjuvant chemoradiation followed by transplantation for perihilar cholangiocarcinoma 3 cm or less in diameter, achieving 5-year survival rates of 65 to 70%.

Colorectal cancer risk in PSC-IBD patients is 4 times higher than in patients with ulcerative colitis alone. Annual surveillance colonoscopy with chromoendoscopy is recommended from the time of PSC diagnosis, regardless of the duration of colitis or disease activity. UDCA may have a chemoprotective effect against colorectal cancer in PSC-UC based on observational data, though this has not been proven in randomized controlled trials.

Gallbladder cancer occurs in 2 to 3% of PSC patients. Annual ultrasound surveillance is recommended, and cholecystectomy should be performed for gallbladder polyps measuring 8 mm or greater, a lower threshold than in the general population. Standard hepatocellular carcinoma screening with ultrasound with or without alpha-fetoprotein every 6 months applies to all PSC patients with established cirrhosis.

<image>A comparison diagram of PBC vs PSC displayed as two parallel columns. Column headers: "Primary Biliary Cholangitis (PBC)" and "Primary Sclerosing Cholangitis (PSC)." Rows for comparison: Demographics (F:M 9:1, age 40-60 vs M:F 2:1, age 30-40), Target (small intrahepatic bile ducts vs large intra/extrahepatic bile ducts), IBD association (rare vs 60-80% UC), Key autoantibody (AMA 90-95% vs pANCA 60-80%), Ig class (IgM elevated vs IgG4 check for overlap), Cholangiography (normal vs beading/stricturing), Histology (florid duct lesion, granulomas vs onion-skin periductal fibrosis), Proven medical therapy (UDCA + second-line agents vs NONE proven), Malignancy risk (low CCA risk vs CCA 7-15% lifetime + high CRC risk in PSC-IBD), Transplant recurrence (minimal vs 20-25% at 10 years). Use visual icons next to each comparison point. Include a shared features box in the center: both are cholestatic liver diseases, both cause progressive biliary fibrosis, both require liver transplant as definitive therapy. Color code: blue for PBC, orange for PSC. Add small representative cholangiogram sketches: normal in PBC, beaded in PSC.</image>

Key Clinical Pearls

• AMA positivity at a titer of 1:40 or greater plus elevated alkaline phosphatase is sufficient for the diagnosis of PBC without liver biopsy.
• Forty percent of PBC patients have an inadequate UDCA response. Elafibranor and seladelpar are newly approved (2024) second-line options with better tolerability than obeticholic acid.
• Obeticholic acid is contraindicated in decompensated cirrhosis and has caused hepatic decompensation and death.
• No proven medical therapy modifies PSC disease progression. Active treatment trials are ongoing.
• High-dose UDCA (28 to 30 mg/kg/day) is harmful in PSC and must not be used.
• PSC carries a 7 to 15% lifetime risk of cholangiocarcinoma. Annual MRCP and CA 19-9 screening is recommended but has limited sensitivity.
• PSC-IBD patients need annual surveillance colonoscopy from the time of PSC diagnosis regardless of colitis duration, as colorectal cancer risk is 4 times higher than in ulcerative colitis alone.
• Anti-gp210 (nuclear rim pattern) and anti-sp100 (nuclear dots) ANAs are highly specific for PBC in AMA-negative cases.

References

1. Lindor KD, et al. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646-659.
2. Lindor KD, et al. AASLD Practice Guidelines: Primary Biliary Cholangitis. Hepatology. 2019;69(1):394-419.
3. Corpechot C, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis (BEZURSO). N Engl J Med. 2018;378(23):2171-2181.
4. Kowdley KV, et al. Efficacy and safety of elafibranor in primary biliary cholangitis (ELATIVE). N Engl J Med. 2024;390(9):795-805.
5. Chapman MH, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-1378.

Read this lecture as Markdown